Compound Ejiao Jiang

Fufang Ejiao Syrup has shown promising clinical effectiveness and safety in treating the syndrome of Qi and blood deficiency in cancer-related fatigue. Expert consensus on clinical application of Fufang Ejiao Syrup in treating syndrome of Qi and blood deficiency in cancer-related fatigue was formulated by a panel of 33 multidisciplinary experts in Chinese and western clinical medicine, methodology, and pharmacy fields from China. They conducted a questionnaire survey among clinicians and systematically reviewed the existing literature on Fufang Ejiao Syrup. The consensus was grounded in the best available evidence, enriched by the experts' expe-rience. It has been reviewed and published by the China Association of Chinese Medicine, with the reference number GS/CACM 340-2023. The internationally recognized GRADE system was used to evaluate the evidence quality of the consensus, resulting in the deve-lopment of 7 recommendations and 20 consensus suggestions through the nominal group technique. The document outlined the indications, traditional Chinese medicine diagnosis, timing of intervention, dosage, criteria for discontinuation, and safety profile of Fufang Ejiao Syrup for treating cancer-related fatigue. Finally, the consensus underwent extensive national consultation and peer review through expert meetings and correspondence reviews. This consensus is applicable to healthcare professionals at all levels of medical institutions and serves as a reference for the rational use of drugs in clinical practices.